PNV logo

PolyNovo Limited Stock Price

ASX:PNV Community·AU$1.1b Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 58 Fair Values set on narratives written by author

PNV Share Price Performance

AU$1.46
-1.07 (-42.29%)
44.9% undervalued intrinsic discount
AU$2.65
Fair Value
AU$1.46
-1.07 (-42.29%)
43.8% undervalued intrinsic discount
AU$2.60
Fair Value
Price AU$1.46
AnalystHighTarget AU$2.60
AnalystConsensusTarget AU$1.97
AnalystLowTarget AU$1.15

PNV Community Narratives

AnalystHighTarget·
Fair Value AU$2.65 44.9% undervalued intrinsic discount

Aging Populations Are Set To Expand Global Advanced Tissue Care

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value AU$1.97 26.1% undervalued intrinsic discount

International Expansion And Regulatory Approvals Will Unlock New Markets

0users have liked this narrative
2users have commented on this narrative
37users have followed this narrative
AnalystLowTarget·
Fair Value AU$1.2 21.7% overvalued intrinsic discount

Global Cost Pressures And Regulatory Risks Will Cripple Future Prospects

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Recent PNV News & Updates

At AU$1.38, Is PolyNovo Limited (ASX:PNV) Worth Looking At Closely?

Sep 28
At AU$1.38, Is PolyNovo Limited (ASX:PNV) Worth Looking At Closely?

PolyNovo Limited (ASX:PNV) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Sep 11
PolyNovo Limited (ASX:PNV) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Returns Are Gaining Momentum At PolyNovo (ASX:PNV)

Jul 18
Returns Are Gaining Momentum At PolyNovo (ASX:PNV)

An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 38% Undervalued

Jun 13
An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 38% Undervalued

PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors

May 22
PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors

PolyNovo Limited Key Details

AU$128.7m

Revenue

AU$13.7m

Cost of Revenue

AU$115.0m

Gross Profit

AU$101.8m

Other Expenses

AU$13.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.019
Gross Margin
89.39%
Net Profit Margin
10.27%
Debt/Equity Ratio
4.5%

PolyNovo Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
3 Rewards

About PNV

Founded
1998
Employees
301
CEO
Robyn Elliott
WebsiteView website
polynovo.com

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Australian Market Performance

  • 7 Days: 1.5%
  • 3 Months: 5.4%
  • 1 Year: 9.2%
  • Year to Date: 9.7%
The market is up 1.5% over the last week, with the Materials sector leading the way, up 3.6%. As for the past 12 months, the market is up 9.2%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›